GLG Partners’s Insys Therapeutics, Inc. INSY Stock Holding History

GLG Partners’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-27,000	Closed	-$248K	–	550
2016 Q4	$248K	Sell	27,000 -3,000	-10%	-$33.9K	0.01%	345
2016 Q3	$354K	Buy	+30,000	New	+$456K	0.01%	397

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCP

Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GLG Partners's INSY Position: Q1 2017 in Review

GLG Partners sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 27,000 shares — an estimated $248K sold.

GLG Partners first reported a position in INSY in Q3 2016 and held it in 2 quarters. The position peaked at $354K in Q3 2016. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

GLG Partners reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
GLG Partners sold 27,000 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $248K.
GLG Partners first reported a position in Insys Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
GLG Partners's Insys Therapeutics, Inc. position peaked at $354K in Q3 2016.
116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on GLG Partners's 13F filing for Q1 2017, filed 15 May 2017.